China Risedronate Sodium Market, 2010-2019 - New Market Study Published

From: Fast Market Research, Inc.
Published: Tue Aug 11 2015

With the ageing population, China has become the country with the largest number of people suffering from osteoporosis which is the most severe disease second to cardiovascular diseases. A nationwide large-scale epidemiological survey has also shown that the incidence of osteoporosis in China is 12.4% and that this figure among women aged 50 and above is 50%. It is estimated that the number of osteoporosis patients and patients with low bone mass will rise to 280 million by 2020.
Currently, drugs for the prevention and treatment of osteoporosis are mainly categorized into bone resorption inhibitor which includes diphosphonate (alendronate, etidronate and risedronate), sex hormone, calcitonin, selective estrogen receptor modulator and bone formation promoter, fluoride product, vitamin D and calcium preparation, parathyroid hormone included.
As a member of the new generation of osteoporosis drugs, risedronate sodium is used for the treatment and prevention of osteoporosis in postmenopausal women. Risedronate sodium has brought in a large amount of sales value in the global market, for example, over USD 1 billion in 2004. According to CRI's market survey, risedronate sodium develops fast after appearing in the Chinese market, annual sales value in sample hospitals rising from less than 40,000 in 2008 to CNY 9.71 million in 2014 and CAGR during this period reaching 156%. Risedronate sodiums in the Chinese market are all produced by local enterprises represented by Kunming Jida Pharmaceutical Co., Ltd, Topfond, Yangtze River Pharmaceutical Group, Jiangsu Chiatai Qingjiang Pharmaceutical Co., Ltd and Beijing SL Pharm, among which Kunming Jida Pharmaceutical Co., Ltd has the largest market share of 84% for sales value in 2014.
With the ageing population, the incidence of osteoporosis will continue to grow. Therefore the market size of risedronate sodium is expected to keep expanding fast in the next few years in China.

Full Report Details at

Readers can get at least the following information from this report:

* market size of risedronate sodium in China
* competitive landscape of risedronate sodium in Chinese market
* price of risedronate sodium made by different enterprises in China
* market outlook of risedronate sodium in China

The author suggests the following groups of people purchase this report:

* manufacturers of osteoporosis drugs
* investors/ research institutions interested in Chinese medicine market
* any interest in the Chinese medicine market, please contact CRI for customized survey service

Companies Mentioned in this Report: Beijing SL Pharm, Kunming Jida Pharmaceutical Co., Ltd, Jiangsu Chiatai Qingjiang Pharmaceutical Co., Ltd, Yangtze River Pharmaceutical Group, Topfond

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- China Piperacillin Sodium and Tazobactam Sodium Market, 2010-2019
- China Sodium Hyaluronate Market, 2010-2019
- China Imipenem and cilastatin sodium Market, 2010-2019
- China Sodium Ibandronate Market, 2010-2019
- China Alendronate Sodium Market, 2010-2019

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email:
Contact Phone: 1-413-485-7001

Visit website »